冠状动脉粥样硬化性心脏病炎症机制及抗炎治疗研究进展
CSTR:
作者:
作者单位:

(中国人民解放军总医院第六医学中心心血管病医学部,北京 100853)

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金(82173450)


Research progress in inflammation-related mechanism and anti-inflammation therapy for coronary artery disease
Author:
Affiliation:

(Department of Cardiology, Sixth Medical Center, Chinese PLA General Hospital, Beijing 100853, China)

Fund Project:

This work was supported by the National Natural Science Foundation of China (82173450)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    冠状动脉粥样硬化性心脏病(CAD)是人类死亡的主要原因之一,其发病机制是由于冠状动脉血管发生动脉粥样硬化病变而引起血管腔狭窄或阻塞,造成心肌缺血、缺氧或坏死而导致的心脏病。在动脉粥样硬化的发生发展过程中,炎症起着至关重要的作用。炎症是冠心病发病机制研究中的一大热点。抗炎治疗药物能否对炎症进行靶向干预并对冠心病患者的预后产生积极的影响日益引起人们的重视。本文扼要综述了介导冠心病发病的关键炎症分子及抗炎药物治疗冠心病的研究进展。

    Abstract:

    Coronary artery disease (CAD) is one of the leading causes of human mortality, and is a common heart condition that involves atherosclerotic plaque formation in the vessel lumen, which then leads to coronary stenosis or occlusion of the vascular lumen, resulting in myocardial ischemia, hypoxia, or necrosis. Inflammation plays a vital role in mediating the occurrence and development of atherosclerosis. Inflammation has been a research hotspot in the study of the pathogenesis of CAD. Increasingly attention has been attracted to whether anti-inflammatory drugs can carry out targeted intervention on inflammation and positively impact the prognosis of CAD patients. In this article, we briefly review the essential inflammatory molecules in the pathogenesis and the research progress of anti-inflammatory drugs for the condition.

    参考文献
    相似文献
    引证文献
引用本文

朱绍宁,胡舜英.冠状动脉粥样硬化性心脏病炎症机制及抗炎治疗研究进展[J].中华老年多器官疾病杂志,2024,23(3):225-228
DOI:10.11915/j. issn.1671-5403.2024.03.048

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-04-24
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-03-22
  • 出版日期:
文章二维码